CVRx (CVRX) Projected to Post Quarterly Earnings on Thursday

CVRx (NASDAQ:CVRXGet Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, January 23rd. Analysts expect CVRx to post earnings of ($0.39) per share and revenue of $14,850.00 billion for the quarter. CVRx has set its Q4 2024 guidance at EPS and its FY 2024 guidance at EPS.

CVRx (NASDAQ:CVRXGet Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same period last year, the business earned ($0.43) EPS. On average, analysts expect CVRx to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Trading Up 1.8 %

Shares of NASDAQ:CVRX opened at $17.62 on Tuesday. The stock has a 50 day moving average of $14.16 and a 200 day moving average of $11.16. The company has a market cap of $427.46 million, a PE ratio of -6.53 and a beta of 1.26. CVRx has a 12-month low of $6.40 and a 12-month high of $29.23. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76.

Analysts Set New Price Targets

CVRX has been the subject of a number of analyst reports. Piper Sandler reissued an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Craig Hallum increased their price target on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. William Blair raised CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $14.00 price objective on shares of CVRx in a research note on Wednesday, October 23rd. Finally, Lake Street Capital lifted their target price on CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Get Our Latest Report on CVRX

About CVRx

(Get Free Report)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

See Also

Earnings History for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.